The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease–Related Genetic Variants

Liu, Zhenqiu; Suo, Chen; Shi, Oumin; Lin, Chunqing; Zhao, Renjia; Yuan, Huangbo; Li, Jin; Chen, Xingdong

doi:10.1016/j.cgh.2020.12.033

Cited by 60 publications

(74 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study by Liu et al reported the genotype data from 160,979 subjects in the UK Biobank, derived from a GWAS chip (Affymetrix UK BiLEVE and UK Biobank Axiom arrays). 20 The impact of MAFLD, especially on hepatic events, was amplified by a high genetic risk score, of which genetic variations in PNPLA3, TM6SF2, and MBOAT7 play principal roles. However, the amplified effects of high genetic risk scores for each of these genes were not found among subjects with lean MAFLD, which was defined as MAFLD with a body mass index <25 kg/m 2 .…”

Section: Geneticsmentioning

confidence: 99%

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Geneticsmentioning

confidence: 99%

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Lean subjects with MAFLD were shown to be under-diagnosed according to classical risk factors [ 35 , 39 ]. The MAFLD phenotype has been associated with worse hepatic outcomes, independent of commonly associated genetic variations [ 41 ]. The MAFLD clinical criteria are easily applicable and validated for the entire spectrum of disease phenotypes [ 42 ].…”

Section: The Evidence To Support the Change In Terminology From Nafld To Mafldmentioning

confidence: 99%

“…Genotyping patients with MAFLD may alert clinicians to recommend close follow-up assessments that healthcare resources may be more efficiently allocated. Liu et al showed that patients with MAFLD had an increased risk for liver cancer, cirrhosis, other liver diseases, cardiovascular disease, renal disease, and cancers [ 41 ]. They also found that the incidence of hepatic and extrahepatic events was increased by a high genetic risk score that included genetic variants in the PNPLA3, TM6SF2, and MBOAT7 genes [ 41 ].…”

Section: The Evidence To Support the Change In Terminology From Nafld To Mafldmentioning

confidence: 99%

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Méndez-Sánchez

Díaz-Orozco

2021

Med Sci Monit

View full text Add to dashboard Cite

In 2020, international consensus guidelines recommended the renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), supported by diagnostic criteria. MAFLD affects up to 25% of the global population. However, the rates of MAFLD are likely to be underestimated due to the increasing prevalence of type 2 diabetes mellitus (T2DM) and obesity. Within the next decade, MAFLD has been projected to become a major cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, as well as the most common indication for liver transplantation in the US. This transition in terminology and clinical criteria may increase momentum and clinical evidence at multiple levels, including patient diagnosis, management, and care, and provide the basis for new research areas and clinical development for therapeutics. The diagnostic criteria for MAFLD are practical, simple, and superior to the existing NAFLD criteria for identifying patients at increased risk of developing progressive liver disease. This Editorial aims to present the historical evolution of the terminology for fatty liver disease and the advantages of diagnosis, patient management, and future research on MAFLD.

show abstract

“…Theoretically, pancreatic involvement is based on the evidence that ACE-2 is usually expressed in the pancreas (exocrine glands and islets) of healthy people, indicating that SARS-CoV-2 might also cause pancreatic injury and potentially contribute to islet damage [ 217 ]. Wang et al, in a retrospective study of 52 patients with COVID-19, described such pancreatic involvement: 17% of patients showed an abnormality in amylase [115 ± 25 U/L (normal value < 90) or lipase [71 ± 34 U/L (normal value < 70)] and six had elevated levels of blood glucose suggestive of pancreatic islet damage.…”

Section: Gastrointestinal Involvement In Covid-19mentioning

confidence: 99%

Twelve Months with COVID-19: What Gastroenterologists Need to Know

et al. 2021

View full text Add to dashboard Cite

Corona virus disease-19 (COVID-19) is the latest global pandemic. COVID-19 is mainly transmitted through respiratory droplets and, apart from respiratory symptoms, patients often present with gastrointestinal symptoms and liver involvement. Given the high percentage of COVID-19 patients that present with gastrointestinal symptoms (GIS), in this review, we report a practical up-to-date reference for the physician in their clinical practice with patients affected by chronic gastrointestinal (GI) diseases (inflammatory bowel disease, coeliac disease, chronic liver disease) at the time of COVID-19. First, we summarised data on the origin and pathogenetic mechanism of SARS-CoV-2. Then, we performed a literature search up to December 2020 examining clinical manifestations of GI involvement. Next, we illustrated and summarised the most recent guidelines on how to adhere to GI procedures (endoscopy, liver biopsy, faecal transplantation), maintaining social distance and how to deal with immunosuppressive treatment. Finally, we focussed on some special conditions such as faecal–oral transmission and gut microbiota. The rapid accumulation of information relating to this condition makes it particularly essential to revise the literature to take account of the most recent publications for medical consultation and patient care. Supplementary Information The online version contains supplementary material available at 10.1007/s10620-021-07158-0.

show abstract

The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease–Related Genetic Variants

Cited by 60 publications

References 30 publications

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Twelve Months with COVID-19: What Gastroenterologists Need to Know

Contact Info

Product

Resources

About